EUVIMEDEUVIMED entdecken
Crossref

Evaluation of the clinical and mechanistic role of MCM2 expression in the prediction of meningioma recurrence after radiotherapy

Chiaki Murakami, Taijun Hana, Tomomi Shimizu, Hirotaka Hasegawa, Haruna Okuno, Hideaki Yokoo, Sumihito Nobusawa, Shuji Momose, Morihiro Higashi, Shunya Hanakita, Soichi Oya

Neurosurgical Focus · 01.09.2026 · 61 (3) · E14

DOI: 10.3171/2026.6.focus26216 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurosurgical Focus, erschienen am 01.09.2026. Verfasst von Chiaki Murakami und 10 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Pathology, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama. Hauptthemen laut MEDLINE: Meningioma, Minichromosome Maintenance Complex Component 2, Meningeal Neoplasms, Neoplasm Recurrence, Local. Die Arbeit nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE Postoperative radiotherapy is an effective treatment for meningiomas; however, treatment response varies among patients. In addition, practical methods for predicting tumor recurrence after radiotherapy have not been well established. Minichromosome maintenance protein 2 (MCM2), a key regulator of DNA replication licensing, was recently implicated in highly proliferative molecular subtypes of meningioma. In this study, the authors evaluated whether MCM2 immunohistochemical expression predicts response to radiotherapy in patients with meningiomas. METHODS The authors retrospectively analyzed the records of patients with WHO grade 1–3 meningiomas treated with resection followed by radiotherapy at a single institution between July 2003 and November 2023. The MCM2 labeling index was assessed immunohistochemically, and patients were stratified into MCM2-high and -low groups using a cutoff of 35%. Progression-free survival (PFS) was defined as the interval from the completion of radiation therapy to postoperative radiological tumor recurrence or regrowth. Patients who showed no progression were censored at their last follow-up. PFS was estimated using Kaplan-Meier analysis and subsequently evaluated with Cox proportional hazards models. To further investigate the biological mechanisms associated with MCM2 expression, comprehensive transcriptomic analyses, including gene set enrichment analysis, was performed to elucidate the molecular processes that occur within MCM2-high tumors. RESULTS The study population included 15 men (42%) and 21 women (58%), with a mean age of 63 years. Ten tumors (28%) were classified as MCM2-high meningiomas and 26 (72%) as MCM2-low meningiomas. High MCM2 expression was significantly associated with WHO grades 2–3 histology and higher Ki-67 labeling indices. During a median follow-up of 2.52 years, tumor progression after radiotherapy occurred in 47% of the patients. High MCM2 expression (HR 8.34, p = 0.03) was significantly associated with shorter PFS and remained an independent predictor of recurrence after adjustment for WHO grade, tumor size, and Ki-67 labeling index. Transcriptomic analyses of MCM2-high tumors revealed upregulation of cell proliferation–related pathways, accompanied by increased signaling through the E2F8–CHEK1 axis associated with radiation resistance and suppression of the TNF-α signaling pathway implicated in radiosensitivity. CONCLUSIONS In meningiomas, high MCM2 expression is associated with early recurrence following radiotherapy. The study findings suggest that this association is driven by diverse biological mechanisms related to cell cycle regulation and radioresistance. Immunohistochemical assessment of MCM2 expression may serve as a practical and accessible biomarker for risk stratification and may support the future development of individualized postoperative radiotherapy strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeningiomaMinichromosome Maintenance Complex Component 2Meningeal NeoplasmsNeoplasm Recurrence, LocalHumansFemaleMaleRetrospective StudiesMiddle AgedAgedAdultBiomarkers, Tumor

Stichwörter der Autor:innen

MCM2biomarkermeningiomaradioresistanceradiotherapyrecurrence

Substanzen

Minichromosome Maintenance Complex Component 2MCM2 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • 1Department of Pathology, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama.
  • 2Department of Neurosurgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama.
  • 3Department of Human Pathology, Gunma University Graduate School of Medicine, Maebashi, Gunma; and.
  • 4Department of Neurosurgery, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.

Zitieren

APA

Murakami, C., Hana, T., Shimizu, T., Hasegawa, H., Okuno, H., Yokoo, H., Nobusawa, S., Momose, S., Higashi, M., Hanakita, S., & Oya, S. (2026). Evaluation of the clinical and mechanistic role of MCM2 expression in the prediction of meningioma recurrence after radiotherapy. Neurosurgical Focus, 61(3), E14. https://doi.org/10.3171/2026.6.focus26216

Vancouver

Murakami C, Hana T, Shimizu T, Hasegawa H, Okuno H, Yokoo H, et al. Evaluation of the clinical and mechanistic role of MCM2 expression in the prediction of meningioma recurrence after radiotherapy. Neurosurgical Focus. 2026;61(3):E14. doi:10.3171/2026.6.focus26216

BibTeX
@article{Murakami2026,
  author = {Murakami, Chiaki and Hana, Taijun and Shimizu, Tomomi and Hasegawa, Hirotaka and Okuno, Haruna and Yokoo, Hideaki and Nobusawa, Sumihito and Momose, Shuji and Higashi, Morihiro and Hanakita, Shunya and Oya, Soichi},
  title = {Evaluation of the clinical and mechanistic role of MCM2 expression in the prediction of meningioma recurrence after radiotherapy},
  journal = {Neurosurgical Focus},
  year = {2026},
  volume = {61},
  number = {3},
  pages = {E14},
  doi = {10.3171/2026.6.focus26216}
}
Kostenlos starten →